Medpace Holdings, Inc. (MEDP) Market Cap

Medpace Holdings, Inc. (MEDP) has a market capitalization of $12.82B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: 5900
Exchange: NASDAQ Global Select
Headquarters: Cincinnati, OH, US
Website: https://www.medpace.com

Loading company profile...

Expand full investment commentary ▼

📘 MEDPACE HOLDINGS INC (MEDP) — Investment Overview

🧩 Business Model Overview

Medpace Holdings Inc (MEDP) is a full-service, scientifically driven contract research organization (CRO) dedicated to accelerating the development of safe and effective therapeutics. Partnering predominantly with small and mid-sized biopharmaceutical and medical device companies, Medpace provides outsourced clinical development services across diverse therapeutic areas globally. The company offers a comprehensive suite of services spanning the full clinical trial lifecycle—from study design and protocol development, through regulatory submission management, site and patient recruitment, data management, biostatistics, and medical writing, culminating in regulatory submission support. Medpace’s vertically integrated business model leverages in-house expertise, robust infrastructure, and advanced technology to deliver tightly managed clinical trials with an emphasis on quality and operational efficiency.

💰 Revenue Streams & Monetisation Model

Medpace generates revenues primarily through contracts with its clients, structured either as fee-for-service arrangements or fixed-price contracts. These contracts typically encompass various services required over the multi-year duration of a clinical trial, including project management, patient recruitment, site management, laboratory and imaging services, data collection, and biostatistical analysis. Revenue recognition is largely driven by the progress and milestones achieved during each project. The company also derives incremental revenues from value-added laboratory, central imaging, and post-approval monitoring services, enabling Medpace to cross-sell and expand share-of-wallet with its existing client base. The backlog of awarded, yet-to-be-completed contracts provides a visible revenue pipeline, further supporting revenue predictability.

🧠 Competitive Advantages & Market Positioning

Medpace differentiates itself in the CRO sector through several key competitive advantages: - **Integrated, Full-Service Platform:** The company maintains a fully integrated clinical development operation, including in-house central laboratory capabilities, reducing coordination costs and timelines versus competitors relying on third-party partners. - **Therapeutic Expertise:** Medpace is recognized for its scientific leadership in complex specialty areas such as oncology, metabolic disease, cardiology, and rare/orphan indications, which are increasingly the focus of drug pipelines. - **High-Touch, Collaborative Model:** Its hands-on, consultative approach, led by medical doctors and scientific experts, appeals particularly to biotech clients seeking tailored solutions and active partnership throughout the drug development process. - **Operational Excellence:** By maintaining consistent processes and limiting geographic dispersion of project teams, Medpace achieves high levels of consistency, quality, and regulatory compliance. - **Niche Focus:** While many larger CROs target wide-ranging client bases, Medpace’s focus on small-to-mid-sized biopharma firms positions it to benefit from the proliferation of innovative therapies originating from these emerging sponsors. - **Strong Backlog Visibility:** The company’s book of awarded contracts underpins future revenues and supports stable cash flows.

🚀 Multi-Year Growth Drivers

Several structural and company-specific forces position Medpace for durable, multi-year secular growth: - **Biopharma R&D Outsourcing Penetration:** The long-term trend toward outsourcing clinical development continues to gain traction, as biopharma companies increasingly seek to lower costs, speed timelines, and access specialized expertise. - **Expansion of Drug Pipelines:** The surge in early-stage venture capital and innovation in areas such as cell and gene therapy, oncology, and rare disease drive heightened demand for CRO services. - **Rising Complexity of Clinical Trials:** The increasing scientific complexity and regulatory scrutiny in drug development favor organizations with deep scientific and operational capabilities. - **International Expansion:** Continued geographic expansion into regions such as Asia-Pacific and Eastern Europe opens new markets and enhances the company’s ability to service global development programs. - **In-house Platform Leverage:** The ability to offer end-to-end services, including central lab and imaging, enables cross-selling opportunities and operating margin expansion as scales increases. - **Industry Consolidation:** As biopharma sponsors increasingly favor vendors capable of managing complex, multinational studies, CROs with established track records and integrated platforms, such as Medpace, stand to win share from disaggregated or sub-scale competitors.

⚠ Risk Factors to Monitor

Investors should consider several inherent risks that could potentially impact Medpace's growth or profitability: - **Biotechnology Funding and Pipeline Volatility:** The company’s client base is heavily weighted toward emerging biopharma sponsors, which may be more sensitive to fluctuations in venture funding, market conditions, or development setbacks. - **Competitive Intensity:** The global CRO industry is highly competitive, with large, well-capitalized peers and new entrants vying for share, potentially pressuring pricing or margins. - **Client Concentration and Project Cancellations:** While Medpace seeks to diversify its client base, it remains exposed to the risk of customer concentration and potential studies being downsized, delayed, or terminated. - **Regulatory and Compliance Risks:** Changes in global regulations governing clinical research, patient privacy, or data use could increase compliance burdens or delays. - **Execution and Talent Management:** Scaling operations while maintaining quality and regulatory compliance depends on recruiting and retaining experienced personnel—a perennial challenge in clinical research. - **Macro and Geopolitical Risks:** Economic downturns, geopolitical instability, or global health crises can disrupt trial enrollment, study timelines, or cross-border operations.

📊 Valuation & Market View

Medpace is commonly valued based on earnings or cash flow multiples relative to both the broader CRO peer set and the overall healthcare services sector. Its strong organic revenue growth profile, robust free cash flow conversion, and operating margins that often exceed industry averages contribute to premium valuation metrics. Medpace’s relatively asset-light business model and high backlog visibility also increase its appeal to long-term investors seeking defensive, growth-oriented exposure. Drivers of valuation include the company’s ability to consistently win new business, expand profitability through operating leverage, and sustain high client retention rates. Market participants may debate the sustainability of Medpace’s above-market growth given its concentrated focus on the more volatile early-stage biotech space and the cyclical nature of R&D funding. However, its differentiated full-service model, scientific expertise, and high-quality execution underpin expectations of durable growth and return on invested capital.

🔍 Investment Takeaway

Medpace Holdings Inc stands out as a best-in-class CRO with a well-integrated, high-touch business model tailored to the needs of the modern biopharma landscape. Its scientific focus, differentiated client engagement strategy, and operational excellence support strong revenue visibility and leading profitability metrics. Secular industry tailwinds—in particular, the ongoing shift toward R&D outsourcing and rising trial complexity—reinforce a multi-year growth runway. Key risks to monitor include exposure to early-stage biotech volatility, sector competition, and evolving regulatory requirements. On balance, Medpace offers investors an attractive vehicle to participate in the growth of outsourced clinical development, with a defensible niche, strong financial characteristics, and potential for long-term value creation.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

MEDP Q4 2025 Earnings Summary

Overall summary: Medpace delivered strong Q4 and FY revenue and earnings growth, though elevated and broad-based cancellations reduced the Q4 net book-to-bill to 1.04 and pressured visibility. Management expects pass-through intensity to moderate through 2026 as metabolic mix normalizes, with guidance calling for high single- to low double-digit revenue and EBITDA growth and slightly higher margins. The tone was constructive on demand (RFPs up, oncology strong) but cautious around cancellation volatility, with hiring set to accelerate to support growth.

Growth

  • Q4 revenue $708.5M, up 32% YoY
  • FY2025 revenue $2.53B, up 20% YoY
  • Q4 EBITDA $160.2M, up 20% YoY; FY EBITDA $557.7M, up 16.1% YoY
  • Q4 diluted EPS $4.67 vs. $3.67 YoY; FY diluted EPS $15.28 vs. $12.63
  • Q4 net new awards $736.6M, up 39.1% YoY; FY net new awards $2.65B, up 18.7% YoY
  • Ending backlog ~$3.0B, up 4.3% YoY; Q4 backlog conversion 23.6%

Business development

  • Q4 net book-to-bill 1.04, pressured by elevated cancellations
  • Oncology strongest area; metabolic remained active but saw higher cancellations
  • RFP activity up slightly QoQ and YoY
  • Expect ~$1.9B of backlog to convert to revenue over next 12 months

Financials

  • Q4 EBITDA margin 22.6% (vs. 24.9% prior year); FY margin 22.0% (vs. 22.8%)
  • Margins impacted by higher reimbursable/pass-through mix driven by therapeutic mix (notably metabolic)
  • Q4 net income $135.1M, up 15.5% YoY; FY net income $451.1M, up 11.6% YoY
  • Customer concentration: top 5 ~25% of FY revenue; top 10 ~35%
  • Q4 cash from operations $192.7M; net DSO -58.7 days
  • Cash $497M at 12/31/25

Capital & funding

  • Repurchased 2.96M shares for $912.9M in 2025; $821.7M authorization remaining
  • 2026 guidance assumes no additional share repurchases
  • 2026 guidance assumes interest income of $24.3M and 29.2M diluted shares
  • 2026 effective tax rate guided to 18.5%–19.5%

Operations & strategy

  • Headcount expected to grow mid- to high-single digits in 2026 (accelerating vs. 2025)
  • Reimbursable costs expected at 41%–42% of 2026 revenue; higher at start of year and moderating by year-end
  • Anticipate flatter quarterly top-line cadence in 2026 vs. prior years
  • Pass-through normalization expected as metabolic mix modestly declines, shifting revenue mix toward direct fees

Market & outlook

  • 2026 revenue guidance: $2.755B–$2.855B (+8.9%–12.8% YoY)
  • 2026 EBITDA guidance: $605M–$635M (+8.5%–13.9% YoY)
  • 2026 EPS guidance: $16.68–$17.50; net income $487M–$511M
  • Guidance based on FX as of 12/31/25 and assumes normal cancellation rates at the midpoint
  • Management characterizes environment as adequate and improving; RFPs modestly higher

Risks & headwinds

  • Q4 cancellations highest in over a year; widespread and skewed to metabolic
  • Further cancellations possible due to program changes or compound performance
  • Margin pressure from elevated reimbursable/pass-through mix
  • Customer concentration risk: top 5/10 customers represent ~25%/~35% of revenue
  • Potential volatility tied to metabolic trial mix and associated pass-through intensity

Sentiment: mixed

📊 Medpace Holdings, Inc. (MEDP) — AI Scoring Summary

📊 AI Stock Rating — Summary

MedP reported quarterly revenues of $708.45 million with an EPS of $4.78, reflecting a net margin of 19.07%. The company generated a robust free cash flow of $262.32 million. Year-over-year growth indicates strong fundamentals with a continued emphasis on increasing operating efficiencies. Revenue growth is solid, supported primarily by strategic market expansions and operational enhancements. The profitability metrics, with a strong net margin, signal effective cost management and pricing strategies, contributing to a stable income stream. Cash flow quality is highlighted by a significant positive free cash flow, underscoring liquidity and operational efficiency. MedP's balance sheet is robust with a net cash position of $383.41 million, indicating low leverage and high financial flexibility. The company hasn’t paid any dividends, focusing on reinvestment and potentially increasing share buybacks, which denotes a prioritization of shareholder value creation through capital appreciation. Analyst sentiment places the stock within a target range of $525 to $660, with a consensus of $588.25, suggesting a generally favorable outlook. The absence of dividends and minimal stock repurchasing initiatives indicate a focus on growth strategies rather than immediate shareholder returns.

AI Score Breakdown

Revenue Growth — Score: 8/10

Steady revenue growth backed by strategic market expansions and operational efficiencies.

Profitability — Score: 9/10

Strong net margin and EPS growth indicate effective cost management and strong pricing power.

Cash Flow Quality — Score: 9/10

Consistent and strong free cash flow generation enhances liquidity and financial flexibility.

Leverage & Balance Sheet — Score: 9/10

Robust net cash position suggests excellent financial health and low leverage.

Shareholder Returns — Score: 6/10

Limited buybacks and absence of dividends suggest a focus on growth over immediate returns.

Analyst Sentiment & Valuation — Score: 7/10

Valuation is favorable relative to analyst targets, reflecting a positive market sentiment.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

SOLV logo

SOLVENTUM CORP (SOLV)

Healthcare

$12.87B

GMED logo

GLOBUS MEDICAL INC CLASS A (GMED)

Healthcare

$12.89B

BBIO logo

BRIDGEBIO PHARMA INC (BBIO)

Healthcare

$12.74B

UHS logo

UNIVERSAL HEALTH SERVICES INC CLAS (UHS)

Healthcare

$13.12B

ELAN logo

ELANCO ANIMAL HEALTH INC (ELAN)

Healthcare

$13.12B

IONS logo

IONIS PHARMACEUTICALS INC (IONS)

Healthcare

$13.14B